Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Biostar Pharma Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule (UTD2)--The World's First Oral Epothilone Anti-Cancer Drug
Biostar Pharma, the US subsidiary of Beijing Biostar Pharmaceuticals which is a synthetic biology-driven biopharma […]
Intellia Therapeutics Announces New Positive Clinical Data from Study of an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
Intellia Therapeutics, a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging […]
Daewoong Pharmaceutical Announce Publication of Phase 3 Study of 'Envlo', a New Treatment for Diabetes
The research results of a Daewoong Pharmaceutical SGLT-2 inhibitor new drug for diabetes, ‘Envlo’, have been […]
Lipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast Agent
Lipella Pharmaceuticals, a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announces […]
Lantern Pharma Announces First Patient Dosed in Study for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer
Lantern Pharma, a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning […]
Bio-Thera Solutions Announces First Patient Dosed in Study for the Treatment of Advanced Solid Tumors
Bio-Thera Solutions, a commercial-stage pharmaceutical company, has announced that dosing has begun in a Phase […]
InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury
InVivo Therapeutics, a research and clinical-stage biomaterials and biotechnology company with a focus on the […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more